A Descriptive Review of Cannabis sativa Patents for Cancer Treatment

Isabela   Fernandes   Pereira; Ana Maria      Santos Oliveira; Anamaria Mendonça      Santos; Denis      de Melo Soares; Mairim Russo      Serafini; Izabel      Almeida Alves

doi:10.2174/1574892818666230213095717

Abstract

Background: Cannabis use for tumor treatment has been explored in several areas, and its potential for tumor remission is currently being studied after the discovery of the endogenous cannabinoid.

Objective: The study aimed to conduct a critical patent review to identify and explore the latest advances and therapeutic strategies using Cannabis to treat cancer.

Methods: The research was carried out in the free and online database Espacenet, using the descriptors “cancer” and "Cannabis or cannabidiol" in the title or abstract. A total of 95 patents were identified for preliminary evaluation in the database. Six duplicate patents were excluded, 12 referring to traditional Chinese medicine and 36 with a title in disagreement with the scope of this review. In addition the final selection involved 21 patents that were in line with the objective of the study.

Results: As observed in the reading of patents, the interest of pharmaceutical industries and researchers and the development of new products to fight cancer have increased in recent years. The main cannabinoids present in the patents are tetrahydrocannabinol, cannabidiol, and hemp. Moreover, the patents were classified and the main applicant countries were the United States followed by Japan, with a higher filing rate in 2019 and, mainly by the industry.

Conclusion: In conclusion we can say that, the importance of parliamentary approval in the cultivation and investments that, in addition to bringing innovation to the industrial sector, enriches research in the area, contributing to the creation of new medicines.

« Previous Next »

[1]
Bray F, Soerjomataram I. The changing global burden of cancer: Transitions in human development and implications for cancer prevention and control. In: Cancer: Disease Control Priorities.  3rd ed. Washington (DC) 2015; 3: p. 23-44.
 [http://dx.doi.org/10.1596/978-1-4648-0349-9_ch2]

[2]
Sindhu SK, Bauman JE. Current concepts in chemotherapy for head and neck cancer. Oral Maxillofac Surg Clin North Am  2019; 31(1): 145-54.
 [http://dx.doi.org/10.1016/j.coms.2018.09.003] [PMID: 30449525]

[3]
Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat Rev  2020; 86: 102019.
 [http://dx.doi.org/10.1016/j.ctrv.2020.102019] [PMID: 32251926]

[4]
Dariš B, Tancer Verboten M, Knez Ž, Ferk P. Cannabinoids in cancer treatment: Therapeutic potential and legislation. Bosn J Basic Med Sci  2019; 19(1): 14-23.
 [http://dx.doi.org/10.17305/bjbms.2018.3532] [PMID: 30172249]

[5]
Birdsall SM, Birdsall TC, Tims LA. The use of medical marijuana in cancer. Curr Oncol Rep  2016; 18(7): 40.
 [http://dx.doi.org/10.1007/s11912-016-0530-0] [PMID: 27215434]

[6]
Davis MP. Cannabinoids for symptom management and cancer therapy: The evidence. J Natl Compr Canc Netw  2016; 14(7): 915-22.
 [http://dx.doi.org/10.6004/jnccn.2016.0094] [PMID: 27407130]

[7]
Abrams DI, Guzman M. Cannabis in cancer care. Clin Pharmacol Ther  2015; 97(6): 575-86.
 [http://dx.doi.org/10.1002/cpt.108] [PMID: 25777363]

[8]
Raghupathi V, Raghupathi W. Innovation at country-level: Association between economic development and patents. J Innov Entrepreneurship  2017; 6(1): 4.
 [http://dx.doi.org/10.1186/s13731-017-0065-0]

[9]
Iftikhar A, Zafar U, Ahmed W, et al. Applications of Cannabis sativa L. in food and its therapeutic potential: From a prohibited drug to a nutritional supplement. Molecules  2021; 26(24): 7699.
 [http://dx.doi.org/10.3390/molecules26247699] [PMID: 34946779]

[10]
Santos AM, dos Santos CC, de Oliveira TB, Serafini MR, Alves IA. What’s new in allergen immunotherapy patents? A review. Crit Rev Ther Drug Carrier Syst  2021; 38(6): 105-25.
 [http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.2021037145] [PMID: 34587430]

[11]
Wyse J, Luria G. Trends in intellectual property rights protection for medical Cannabis and related products. J Cannabis Res  2021; 3(1): 1.
 [http://dx.doi.org/10.1186/s42238-020-00057-7] [PMID: 33526141]

[12]
McPartland JM. Cannabis systematics at the levels of family, genus, and species. Cannabis Cannabinoid Res  2018; 3(1): 203-12.
 [http://dx.doi.org/10.1089/can.2018.0039] [PMID: 30426073]

[13]
Lee JW. Composition for anti-cancer, reducing anti-cancer side effects and suppressing cancer metastasis, including Cannabis extract as active ingredient. Patent US 2021236570A1, 

[14]
De Backer B, Debrus B, Lebrun P, et al. Innovative development and validation of an HPLC/DAD method for the qualitative and quantitative determination of major cannabinoids in cannabis plant material. J Chromatogr B Analyt Technol Biomed Life Sci  2009; 877(32): 4115-24.
 [http://dx.doi.org/10.1016/j.jchromb.2009.11.004] [PMID: 19932642]

[15]
Mehmedic Z, Chandra S, Slade D, et al. Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci  2010; 55(5): 1209-17.
 [http://dx.doi.org/10.1111/j.1556-4029.2010.01441.x] [PMID: 20487147]

[16]
Grof CPL. Cannabis, from plant to pill. Br J Clin Pharmacol  2018; 84(11): 2463-7.
 [http://dx.doi.org/10.1111/bcp.13618] [PMID: 29701252]

[17]
Chen T, Hu J. Medicine for treating pancreatic cancer. Patent: CN106074709 (A), 2016.

[18]
Chen T, Hu J. Application of whole hemp extract in preparation of pancreatic cancer treating drug. Patent: CN105943615 (A), 2016.

[19]
Kim TW, Kim TJ. Composition for anti-cancer decline in anti-cancer side effects and suppression of cancer metastasis comprising extract of Cannabis sativa l. Patent: KR102269816 (B1), 2021.

[20]
Luan Y, Zheng S, Li Z, Li X. Pharmaceutical composition for treating thyroid cancer and preparation method thereof. Patent : CN110354170 (A), 2019.

[21]
Luan Y, Zheng S, Li Z, Li X. Drug composition for treating endometrial cancer. Patent: CN110063953 (A), 2021.

[22]
Kovalchuk O, Li D, Rodriguez-Juarez RC, et al. Novel cannabis lines and extracts for treating skin disorders. Patent: WO2020129045 (A1), 2020.

[23]
Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int J Mol Sci  2018; 19(3): 833.
 [http://dx.doi.org/10.3390/ijms19030833] [PMID: 29533978]

[24]
Seltzer ES, Watters AK, MacKenzie D Jr, Granat LM, Zhang D. Cannabidiol (CBD) as a promising anti-cancer drug. Cancers  2020; 12(11): 3203.
 [http://dx.doi.org/10.3390/cancers12113203] [PMID: 33143283]

[25]
Stella B, Baratta F, Della Pepa C, Arpicco S, Gastaldi D, Dosio F. Cannabinoid formulations and delivery systems: Current and future options to treat pain. Drugs  2021; 81(13): 1513-57.
 [http://dx.doi.org/10.1007/s40265-021-01579-x] [PMID: 34480749]

[26]
Karelis H, Gordon M, Smith S, Washer S. Cannabis composition. Patent: AU2021205115 (A1), Ag, 12, 2021.

[27]
Martinenghi LD, Jønsson R, Lund T, Jenssen H. Isolation, purification, and antimicrobial characterization of cannabidiolic acid and cannabidiol from Cannabis sativa L. Biomolecules  2020; 10(6): 900.
 [http://dx.doi.org/10.3390/biom10060900] [PMID: 32545687]

[28]
Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol  2005; 144(8): 1032-6.
 [http://dx.doi.org/10.1038/sj.bjp.0706134] [PMID: 15700028]

[29]
Lee DH, Oh SC, Lee SI, Jeong SY. Pharmaceutical composition containing cannabidiol extract for preventing or treating colon cancer. Patent: KR20190098649 (A), 2019.

[30]
Young Go Y, Ra Kim S, Yeon Kim D, Chae S-W, Song J-J. Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep  2020; 10(1): 20622.
 [http://dx.doi.org/10.1038/s41598-020-77674-y]

[31]
Ahmed Saeed AL-Japairai K, Mahmood S, Hamed Almurisi S,	et al. Current trends in polymer microneedle for transdermal drug delivery. Int J Pharm  2020; 587: 119673.
 [http://dx.doi.org/10.1016/j.ijpharm.2020.119673] [PMID: 32739388]

[32]
Boshuizen J, Peeper DS. Rational cancer treatment combinations: An urgent clinical need. Mol Cell  2020; 78(6): 1002-18.
 [http://dx.doi.org/10.1016/j.molcel.2020.05.031] [PMID: 32559422]

[33]
Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma subclassifications and their clinical significance. Neurotherapeutics  2017; 14(2): 284-97.
 [http://dx.doi.org/10.1007/s13311-017-0519-x] [PMID: 28281173]

[34]
Velasco DG, Guzman PM, Lorente M, et al. Cannabinoid combined with non-cannabinoid chemotherapeutic agent (e.g., serm or alkylating agent). Patent: JP2015057411 (A), 2015.

[35]
Scott KA, Dalgleish AG, Liu WM. The combination of cannabidiol and Δ9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Mol Cancer Ther  2014; 13(12): 2955-67.
 [http://dx.doi.org/10.1158/1535-7163.MCT-14-0402] [PMID: 25398831]

[36]
Mcallister SD, Desprez PY. Methods and compositions for treating cancer. Patent: US2015320720 (A1), 2015.

[37]
Derkinderen P, Valjent E, Toutant M, et al. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci  2003; 23(6): 2371-82.
 [http://dx.doi.org/10.1523/JNEUROSCI.23-06-02371.2003] [PMID: 12657697]

[38]
Parolaro D. Phytocannabinoids in the treatment of cancer. GB2554592 (A), 2018.

[39]
Tomko AM, Whynot EG, Ellis LD, Dupré DJ. Anti-cancer potential of cannabinoids, terpenes, and flavonoids present in Cannabis. Cancers  2020; 12(7): 1985.
 [http://dx.doi.org/10.3390/cancers12071985] [PMID: 32708138]

[40]
Lamensdorf I, Levy Y. Fixed dose combination of cannabinoids and medical mushrooms for prevention and treatment of cancer, inflammatory or immune-mediated inflammatory diseases. Patent: WO2020188577 (A1), 2020.

[41]
Romero P, Peris A, Vergara K, Matus JT. Comprehending and improving cannabis specialized metabolism in the systems biology era. Plant Sci  2020 Sep; 298: 110571.
 [http://dx.doi.org/10.1016/j.plantsci.2020.110571]

[42]
Hesami M, Pepe M, Alizadeh M, Rakei A, Baiton A, Phineas Jones AM. Recent advances in cannabis biotechnology. Ind Crops Prod  2020; 158: 113026.
 [http://dx.doi.org/10.1016/j.indcrop.2020.113026]

[43]
Ross RA, Parolaro D. Phytocannabinoids for use in the treatment of cancer. Patent: MX2014002873 (A), 2014.

[44]
Stott C, Duncan M, Hill T. Active pharmaceutical ingredient (api) comprising cannabinoids for use in the treatment of cancer. Patent: US2017143642 (A1), 2017.

[45]
Scialdone MA. Hydrogenation of cannabis oil. Patent: US2019030102 (A1), 2019.

[46]
Connor JP, Stjepanović D, le Foll B, Hoch E, Budney AJ, Hall WD. Cannabis use and cannabis use disorder. Nat Rev Dis Primers  2021; 7(16)
 [http://dx.doi.org/10.1038/S41572-021-00247-4]

[47]
Pattnaik F, Nanda S, Mohanty S, et al. Cannabis: Chemistry, extraction and therapeutic applications. Chemosphere  2022; 289: 133012.
 [http://dx.doi.org/10.1016/j.chemosphere.2021.133012]

[48]
Turgeman I, Bar-Sela G. Cannabis for cancer - illusion or the tip of an iceberg: a review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology. Expert Opin Investig Drugs  2019; 28(3): 285-96.
 [http://dx.doi.org/10.1080/13543784.2019.1561859]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1574892818666230213095717	Print ISSN 1574-8928
Publisher Name Bentham Science Publisher	Online ISSN 2212-3970

Recent Patents on Anti-Cancer Drug Discovery

A Descriptive Review of Cannabis sativa Patents for Cancer Treatment

Abstract Play Pause

Related Journals

Related Books

Abstract